Discover groundbreaking research on pulmonary fibrosis and a potential new treatment target that could revolutionize lung ...

STOCKHOLM, SE / ACCESS Newswire / September 30, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ...

A research group from the National Cancer Research Center (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult. The ...

Figure 3. Conceptual framework for aging alignment in disease models and therapeutic development. This schematic illustrates the spectrum of aging-related diseases (ARDs) based on their mechanistic ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...

Rheumatoid arthritis (RA) was causally linked to the development of idiopathic pulmonary fibrosis, with shared plasma factors CC motif chemokine ligand 2 (CCL2) and CXC motif chemokine ligand 2 (CXCL2 ...

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by the excessive accumulation of extracellular matrix components, leading to a gradual decline in lung ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...

In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...

Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p The views and opinions expressed herein are the views ...

The future is here now: Use of proteomic testing in pulmonary nodule management in an underserved population in Brooklyn, NY. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...